Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized Phase II clinical trial of zabadinostat in liver cancer patients with acquired resistance to immune checkpoint inhibitors (ICIs)

Next Previous
Trial Profile

A randomized Phase II clinical trial of zabadinostat in liver cancer patients with acquired resistance to immune checkpoint inhibitors (ICIs)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zabinostat (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Celleron Therapeutics; IngenOx Therapeutics

Most Recent Events

  • 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
  • 20 Aug 2022 New trial record
  • 15 Aug 2022 According to a Celleron Therapeutics media release, the company has received a study grant from the Hong Kong government General Research Fund for financing the trial in partnership with the Chinese University of Hong Kong.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top